GE Healthcare's clinical research data of its positron emission tomography (PET) investigational amyloid imaging agent Flutemetamol showed highly consistent image interpretation and showed comparable in vitro binding to the Pittsburgh Compound-B ([C-11]PiB)) investigational imaging agent.
Flutemetamol is one part of a broad portfolio of diagnostic solutions that GE Healthcare is currently developing in the Alzheimer’s field.
The drug is in phase III development being studied to detect beta amyloid using PET brain scans.
Readers blinded to clinical information demonstrated high inter- and intra-reader agreement rates when interpreting the brain distribution of Flutemetamol as normal and abnormal images.
Flutemetamol imaging was consistent with the understanding that normal pressure hydrocephalus (NPH), a progressive condition associated with dementia, gait abnormalities and urinary incontinence, represents a heterogeneous population with evidence of AD pathology.
6-CN-Flutemetamol is comparable to 6-CN-Pittsburgh Compound-B (PiB) in its ability to bind to beta amyloid in vitro.
GE Healthcare Medical Diagnostics MI PET Segment leader Jonathan Allis said use of PET imaging scans to detect AD pathology may enable physicians to make a more accurate and earlier diagnosis of the disease.